Delivery Order SPE2DB24D2003-SPE2DB25FXLT1
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $9,523.55 to AmerisourceBergen Drug Corp for the supply of Gvoke HypoGen 2-pack auto-injectors (1 mg/0.2 mL) on August 7, 2025, with an ultimate completion date of August 8, 2025. This competitively awarded, firm fixed-price contract contains no set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a small-value transaction within...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for GVOKE HypopenTM auto-injector units (2-pack, 1 mg/0.2 mL formulation) with a ceiling value of $19,036.29. This competitively awarded, firm fixed-price delivery order was issued on July 23, 2025, with an ultimate completion date of July 24, 2025, and represents a child order under AmerisourceBergen's larger pharmaceutical supply agreement. The contract specifies performance at the contractor's Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of Gvoke HypoPen 2-pack auto-injectors (1 mg/0.2 mL) with a ceiling value of $2,832.92. This is a firm fixed-price delivery order with an ultimate completion date of August 18, 2025, and will be performed at the company's corporate office location in Conshohocken, Pennsylvania. The award was competitively awarded with no set-aside designation. This delivery order is issued...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for GVOKE HypoPen 2-Pack (1 mg/0.2 mL) with a ceiling value of $3,737.84 under a firm fixed price contract type. The delivery order was non-competitive with no set-aside designation and carries an ultimate completion date of August 4, 2025. Performance will be executed at AmerisourceBergen's Conshohocken, Pennsylvania facility, the company's corporate headquarters. This delivery order is issued as a child...
- The Defense Logistics Agency awarded a delivery order valued at $2,501.51 to AmerisourceBergen Drug Corp for Gvoke HypoPen auto-injectors (1 mg/0.2 mL, 2-pack). This competitive award, issued on July 28, 2025, represents a firm fixed-price delivery order with an ultimate completion date of July 29, 2025, and will be performed at the vendor's corporate office in Conshohocken, Pennsylvania. No set-aside designation was applied to this procurement, indicating open competition among eligible...
- The Defense Logistics Agency awarded a delivery order valued at $4,087.62 to AmerisourceBergen Drug Corp for GVOKE HypoPen 2-Pack 1 mg/0.2 ml auto-injectors. This competitively awarded, firm fixed-price contract was executed on August 11, 2025, with an ultimate completion date of August 12, 2025. The contract involves delivery to Conshohocken, Pennsylvania, where AmerisourceBergen Drug Corp maintains its corporate headquarters. No set-aside provisions were utilized for this award. This...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $29,684.93 to AmerisourceBergen Drug Corp for the supply of GVOKE HypoPin 2-pack auto-injectors (0.5mg/0.1ml) with an ultimate completion date of August 18, 2025. This firm fixed-price, non-set-aside contract was awarded competitively on August 15, 2025, with performance at the contractor's facility in Conshohocken, Pennsylvania. The GVOKE HypoPin is a glucagon emergency injection system used to treat severe hypoglycemia in...
- The Defense Logistics Agency awarded a $1,187.00 firm fixed-price delivery order to AmerisourceBergen Drug Corp for GVOKE 1 mg/0.2 mL kits on July 30, 2025, with completion scheduled for July 31, 2025. This award was not set-aside and represents a competitively awarded transaction under AmerisourceBergen's larger contract vehicle with DLA. GVOKE is a glucagon emergency injection kit used for treating severe hypoglycemia in patients with diabetes, making this a critical pharmaceutical supply...
- The Defense Logistics Agency awarded a delivery order valued at $1,012.14 to AmerisourceBergen Drug Corp for GVOKE 1 MG/0.2 ML emergency glucagon kits on July 28, 2025, with completion scheduled for July 29, 2025. This competitively awarded, firm fixed-price contract involves no set-aside designation and will be performed at the awardee's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical federal medical procurement vendor,...
- This is a firm-fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $3,494.26, is for the delivery of GVOKE HYPOPEN 2-PK 1 MG/0.2 ML 0.2ML medical devices. The contract has a period of performance through March 25, 2025. Amerisourcebergen holds a larger $999,999,999 Indefinite Delivery Contract with the DLA Troop Support Medical, which serves as a...
- SPE2DB24D2003Indefinite Delivery Contract
- SPE2DB24D2003-SPE2DB25FXLT1Delivery Order
The Defense Logistics Agency awarded a $2,522.44 firm fixed price delivery order to AmerisourceBergen Drug Corp for one package of Gvoke HypoGel 1 mg/0.2 mL auto-injector. The order is set to be completed by August 18, 2025, with performance at the contractor's facility in Conshohocken, Pennsylvania. This delivery order was competitively awarded with no set-aside designation and represents a small-value transaction within the company's broader federal pharmaceutical supply portfolio. This award is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026. As a major pharmaceutical distributor and critical vendor for federal medical procurement, AmerisourceBergen leverages this comprehensive prime vendor agreement to supply a wide range of pharmaceutical products and medical supplies to support military healthcare systems globally. The Gvoke HypoGel product delivered under this order is a glucagon emergency injection device used for treating severe hypoglycemia in patients with diabetes, reflecting the company's role in delivering specialized medical commodities across multiple therapeutic domains to the Defense Health Agency and other government healthcare customers.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.5k | 8/15/25 |